WY-14643 (Pirinixic Acid): Selective PPARα Agonist for Metabolic and Inflammatory Research

Executive Summary: WY-14643, also known as Pirinixic Acid, is a research-grade, selective agonist for peroxisome proliferator-activated receptor alpha (PPARα) with an IC₅₀ of 10.11 µM in human systems (APExBIO). It modulates lipid metabolism, inflammation, and energy homeostasis by activating PPARα and, upon α-substitution, PPARγ (DOI:10.21203/rs.3.rs-5704972/v1). In animal models, daily oral dosing at 3 mg/kg for two weeks improves insulin sensitivity and reduces visceral and liver fat without causing weight gain. WY-14643 downregulates VCAM-1 in endothelial cells, lowering inflammatory cell adhesion (Related Article). The compound is insoluble in water, but highly soluble in DMSO and ethanol, and must be stored at -20°C for stability (APExBIO).

Biological Rationale

WY-14643 addresses key mechanisms in metabolic syndrome, type 2 diabetes, and inflammation. PPARα is a nuclear receptor that regulates genes involved in fatty acid β-oxidation, lipid transport, and inflammatory signaling (DOI:10.21203/rs.3.rs-5704972/v1). Selective activation of PPARα by WY-14643 results in improved lipid profiles and reduced inflammatory responses, as seen in animal and cellular studies. Dual agonism with PPARγ, achievable via chemical modification, allows for broader regulation of glucose and lipid metabolism (Related Article). This is critical for translational research in metabolic disorders, non-alcoholic fatty liver disease (NAFLD), and cardiovascular inflammation. The ability of WY-14643 to inhibit VCAM-1 further extends its relevance to endothelial cell inflammation models.

Mechanism of Action of WY-14643 (Pirinixic Acid)

WY-14643 binds to and activates PPARα, a ligand-activated transcription factor in the nuclear receptor family. Upon activation, PPARα forms a heterodimer with the retinoid X receptor (RXR) and binds to PPAR response elements (PPREs) in target gene promoters. This triggers transcription of genes involved in lipid catabolism, fatty acid transport, and anti-inflammatory pathways (DOI:10.21203/rs.3.rs-5704972/v1). Aliphatic α-substitution on the WY-14643 scaffold increases its activity towards both PPARα and PPARγ, resulting in dual agonism at low micromolar concentrations. In endothelial cells, WY-14643 downregulates vascular cell adhesion molecule-1 (VCAM-1), reducing leukocyte adhesion and transmigration. The drug’s modulation of fatty acid metabolism leads to decreased plasma triglycerides, improved insulin sensitivity, and reduced hepatic steatosis in vivo. Notably, WY-14643 also influences Kupffer cell activation and TNF-α mediated inflammation, making it a versatile tool for metabolic and inflammatory research.

Evidence & Benchmarks

• WY-14643 acts as a potent and selective PPARα agonist with an IC₅₀ of 10.11 µM for human PPARα (APExBIO).
• α-Substituted analogs of WY-14643 achieve balanced dual PPARα/γ agonism in the low micromolar range (Related Article).
• WY-14643 reduces VCAM-1 expression and inflammatory cell adhesion in endothelial cells (See Evidence).
• In high-fat diet rat models, 3 mg/kg/day oral WY-14643 for 2 weeks lowers plasma glucose, triglycerides, leptin, muscle triglycerides, and long-chain acyl-CoAs, while increasing insulin sensitivity and reducing visceral and liver fat content, without inducing weight gain (DOI:10.21203/rs.3.rs-5704972/v1).
• WY-14643 is insoluble in water, but soluble in DMSO (≥16.2 mg/mL) and ethanol (≥48.8 mg/mL with ultrasonic aid); optimal dissolution is achieved by warming to 37°C and ultrasonic shaking (APExBIO).
• WY-14643 modulates PPARα-mediated tissue factor (TF) expression, affecting tumor microenvironment and inflammation (DOI:10.21203/rs.3.rs-5704972/v1).

Applications, Limits & Misconceptions

WY-14643 is primarily employed to dissect PPARα signaling in metabolic and inflammatory models. It is used in research on metabolic syndrome, NAFLD, insulin resistance, cardiovascular inflammation, and tumor microenvironments. The compound allows for precise modulation of lipid metabolism genes and cytokine responses. However, its utility is bounded by several factors:

Common Pitfalls or Misconceptions

• WY-14643 is not suitable for long-term solution storage; solutions should be freshly prepared due to stability concerns (APExBIO).
• Water is not a suitable solvent; WY-14643 is insoluble and will precipitate. Use DMSO or ethanol for dissolution.
• It is not a pan-PPAR agonist; significant activity is restricted to PPARα and, with certain modifications, PPARγ. It does not activate PPARδ effectively.
• Animal and cellular effects may not fully translate to human clinical outcomes due to species-specific PPAR expression and ligand sensitivity (See Discussion).
• WY-14643 should not be used as a therapeutic agent in humans; it is for research use only.

This article extends the mechanistic focus of previous reviews by integrating quantitative benchmarks and solubility data for experimental reproducibility.

Workflow Integration & Parameters

For optimal use, dissolve WY-14643 in DMSO at ≥16.2 mg/mL or in ethanol at ≥48.8 mg/mL with ultrasonic assistance. Warm solutions to 37°C and use brief ultrasonic shaking to ensure complete dissolution. Do not store solutions long-term; prepare fresh aliquots prior to each experiment. Store the solid compound at −20°C in a desiccated environment. In vivo dosing in rodents typically ranges from 1–3 mg/kg/day, while in vitro concentrations commonly span 1–20 µM depending on cell type and endpoint. Always verify batch identity and purity, especially for translational applications. For detailed mechanistic and application context, see the APExBIO product page (A4305).

Conclusion & Outlook

WY-14643 (Pirinixic Acid) is a benchmark tool for dissecting PPARα-mediated metabolic and inflammatory pathways in preclinical research. Its dual PPARα/γ agonist potential, robust in vivo and in vitro efficacy, and well-characterized solubility and stability parameters make it indispensable for studies of metabolic syndrome, NAFLD, and endothelial inflammation. As PPAR signaling remains a central target in metabolic and tumor microenvironment research, WY-14643 continues to provide reproducible, atomic insights, supporting both basic discovery and translational science. For advanced protocols and reagent specifications, refer to APExBIO.